

SLR/du 11/14/05 4239-66645-01 452196 E-090-1996/0-US-06

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere et al.

Application No. 10/700,313

Filed: October 31, 2003

Confirmation No. 5461

For: CC CHEMOKINE RECEPTOR 5 DNA, NEW
ANIMAL MODELS AND THERAPEUTIC
AGENTS FOR HIV INFECTION

Examiner: John D. Ulm

Art Unit: 1649

Attorney Reference No. 4239-66645-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed November 15, 2005

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

11/21/2005 DEMMANU1 00000036 10700313

01 FC:1806


180.00 DP


One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

cc: Docketing

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-66645-01
Application Number	10/700,313
Filing Date	October 31, 2003
First Named Inventor	Combadiere
Art Unit	1649
Examiner Name	John D. Ulm

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	0 310 136 A2	04/05/1989	The Rockefeller University

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Combadiere et al., "Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor," <i>J. Biol. Chem.</i> 270:16491-16494 (1995).
		Feng et al., "HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor," <i>Science</i> 272:872-877 (1996).
		Gong et al., "RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors," <i>J. Biol. Chem.</i> 271:10521-10527 (1996).
		Rucker et al., "Regions in β -Chemokine Receptors CCR5 and CCR2b that Determine HIV-1 Cofactor Specificity," <i>Cell</i> 87:437-446 (1996).
		Database PIR2 Accession number G02653, 21 December 1990 (also referred to as EMBL Accession No. A43113, July 12, 1996).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.